STOCK TITAN
  1. Home
  2. DRNA

Dicerna Stock Price, News & Analysis

DRNA NASDAQ

Company Description

Dicerna (NASDAQ: DRNA) is a publicly traded pharmaceutical preparation manufacturing company in the Manufacturing sector.

DRNA stock has gained 71.5% over the past year.

This page provides a comprehensive overview of DRNA stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
+71.54%
Performance 1 year
$0.0
Market Cap
77.9M
Shares outstanding

Dicerna (DRNA) stock. Over the past 12 months, the stock has gained 71.5%.

Latest News

View All
—

Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition

acquisition
+0.58%

Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna

acquisition
+78.71%

Novo Nordisk to Acquire Dicerna

acquisition
+0.09%

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

+0.09%

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

clinical trial
+0.40%

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

earnings

Dicerna has 10 recent news articles. Of the recent coverage, 8 articles coincided with positive price movement and 1 with negative movement. Key topics include acquisition, clinical trial, earnings, conferences. View all DRNA news →

SEC Filings

View All

No SEC filings available for DRNA.

Financial Highlights

View Full Financials
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

DRNA Company Profile & Sector Positioning

Dicerna (DRNA) operates in the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.